Dr. Silke Gillessen is joined by Drs. Thomas Zilli (specializing in radiation oncology), Jochen Walz (urology) and Ken Hermann (nuclear medicine) to discuss the top highlights from 2024 in the prostate cancer field from each of their unique perspectives. ...
The Uromigos: Prostate Cancer
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news on prostate cancer.
Advertisement
Chuck Ryan, MD, joins the podcast to discuss various aspects of AR inhibition in prostate cancer.
Brian and Tom are joined by Dr. Chris Sweeney and Rob Jones to discuss the merits of various ARPIs in prostate cancer.
Returning guests Bertrand Tombal and Silke Gillessen join the podcast to dive into data from the 2024 APCCC.
Special guest Bertrand Tombal of Manchester Cancer Research Centre focuses on the historic and current data of AR inhibition
Listen to the podcast format of the panel on radioligand data in prostate cancer from Uromigos Live 2024.
Listen to the podcast format of the panel on T cell directed therapy in prostate cancer from Uromigos Live 2024.
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024.
Dr. Nima Sharifi joins The Uromigos to discuss mechanisms of resistance to hormone therapy in prostate cancer.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Dr. Nick James joins the podcast to discuss the recent Lancet Commission paper on prostate cancer.
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
...
Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature.
Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer.
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024.
Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April.
The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023.
Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer.
Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic.
Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study.
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA.
We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one.
Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers.
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.